title: Combination oral prednisone and intravenous immunoglobulin in the treatment of scleromyxedema.
abstract: BACKGROUND
  Scleromyxedema is a clinical variant of the rare disease papular mucinosis that has both cutaneous and systemic manifestations. Treatment options are numerous and tend to be associated with serious potential side effects and frequent relapse.
  
  
  OBJECTIVE
  We report a case of scleromyxedema treated with low-dose oral prednisone and intravenous immunoglobulin (IVIg). This is followed by a review of the literature.
  
  
  CONCLUSIONS
  IVIg is being used for a growing number of inflammatory and immune disorders. It is being increasingly reported as a successful treatment for scleromyxedema. Although our patient succumbed to the disease, combination therapy with prednisone and IVIg provided temporary symptomatic, laboratory, and clinical improvement of the condition. Optimization of this therapeutic strategy is thus indicated for the management of scleromyxedema.
authors.affiliation: University Dermatology Centre, University of Alberta, Edmonton, AB, Canada.
authors.forename: Candace
authors.initials: C
authors.lastname: Majeski
authors.forename: Muba
authors.initials: M
authors.lastname: Taher
authors.forename: Parbeer
authors.initials: P
authors.lastname: Grewal
authors.forename: Marlene
authors.initials: M
authors.lastname: Dytoc
authors.forename: Gilles
authors.initials: G
authors.lastname: Lauzon
mesh_terms: D000369:Aged, 80 and over; D017809:Fatal Outcome; D005260:Female; D005938:Glucocorticoids / Q000008:administration & dosage / Q000627:therapeutic use*; D006801:Humans; D016756:Immunoglobulins, Intravenous / Q000627:therapeutic use*; D017512:Lichenoid Eruptions / Q000188:drug therapy*; D017520:Mucinoses / Q000188:drug therapy*; D011241:Prednisone / Q000008:administration & dosage / Q000627:therapeutic use*
chemical_list: D005938:Glucocorticoids; D016756:Immunoglobulins, Intravenous; D011241:Prednisone